AI-generated · cited to primary sources · not investment advice
Management expects Bangladesh patient volumes to recover, with at least 60% having returned in October, and is exploring additional international markets including Uzbekistan, Africa, Indonesia and Iraq. — target: At least 60% of Bangladesh patients returning
“Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekistan, etcetera. So those that are surrounding markets, Africa, some with Indonesia, Iraq.”
See the full cited Management analysis of Apollo Hospitals
Higher-complexity specialties were growing faster than the hospital business overall: cardiac, oncology, neurosciences, gastroenterology and orthopaedics recorded 6% volume growth and 14% revenue growth year on year. Management attributed higher revenue per patient largely to a richer mix of cases. This is a favorable shift toward more complex care. (5 expanding)
“Cardiac, oncology, neurosciences, gastro and orthopaedics - which remain a key growth engine, delivering a 6% volume and 14% revenue growth on a year-on-year basis.”
The Bangladesh patient reduction lowered Healthcare Services revenue by about 1% in Q2 FY26. Management said at least 60% of Bangladesh patient volumes had begun returning by October and described exploring other international markets, including Uzbekistan, Africa, Indonesia and Iraq. The later baseline says Bangladesh volumes had recovered to 60%–70% of their former peak and international-patient revenue was up 26% YoY, supporting a favorable recovery and diversification direction. The transcript gives no international revenue share. (2 expanding)
“The reduction in number of patients from Bangladesh has had a 1% impact on Healthcare Services revenue in Q2 FY26.”
See the full cited Business Model analysis of Apollo Hospitals
The supplied signal describes Q1 FY27, which is outside this November 2025 presentation. In this document, hospital revenue growth is 9% in Q2 FY26 after 10% in H1 FY26; inpatient-volume growth is about 2% in both periods, while revenue per inpatient is up about 9% in both. The latest quarter therefore shows slower revenue growth, mostly from low patient-volume growth rather than a change in revenue per patient. (1 decelerating, 1 steady, 1 new trend across 3 signals)
“Healthcare Services Revenue grew by 9% in Q2FY26 (Inpatient Volume grew by 2% ; Price of and case mix of 7%). ... Average Revenue per In patient grew by 9% to ₹173,318 in Q2FY26”
See the full cited Future Growth analysis of Apollo Hospitals
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.